ArticleClinical kidney journal2026
Elevated leucine-rich alpha-2 glycoprotein levels and mortality risk in end-stage renal disease: evidence for gender differences.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leucine-rich α-2 glycoprotein (LRG) is an inflammation-related serum protein implicated in cardiovascular pathology. Its prognostic role in patients with end-stage renal disease (ESRD) remains unclear. We investigated the association between serum LRG levels and all-cause mortality in maintenance haemodialysis patients, with a focus on sex-specific effects. Methods: In this prospective cohort study, 313 stable haemodialysis patients (206 males, 107 females) were enrolled and followed for 5 years. Baseline serum LRG concentrations were quantified by ELISA. Receiver operating characteristic (ROC) analysis identified an optimal mortality risk cut-off (45.5 µg/ml). Survival analyses used Kaplan-Meier curves and multivariable Cox regression models adjusted for demographic, clinical, and laboratory covariates. Analyses were stratified by sex. Results: During follow-up, 103 deaths occurred (78 males, 25 females). Higher LRG levels were significantly associated with increased mortality risk in males (log-rank Conclusions: Elevated serum LRG independently predicts all-cause mortality in male, but not female, haemodialysis patients. These findings highlight the potential of LRG as a sex-specific biomarker for risk stratification in ESRD and underscore the need for mechanistic studies on sex differences in LRG-related pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.